PL3064579T3 - Kompozycje farmaceutyczne i zastosowania medyczne uzyskanych metodami inżynierii ludzkich arginaz - Google Patents

Kompozycje farmaceutyczne i zastosowania medyczne uzyskanych metodami inżynierii ludzkich arginaz

Info

Publication number
PL3064579T3
PL3064579T3 PL16163214T PL16163214T PL3064579T3 PL 3064579 T3 PL3064579 T3 PL 3064579T3 PL 16163214 T PL16163214 T PL 16163214T PL 16163214 T PL16163214 T PL 16163214T PL 3064579 T3 PL3064579 T3 PL 3064579T3
Authority
PL
Poland
Prior art keywords
pharmaceutical compositions
medical uses
engineered human
human arginases
arginases
Prior art date
Application number
PL16163214T
Other languages
English (en)
Inventor
George Georgiou
Everett Stone
Original Assignee
Aerase, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerase, Inc. filed Critical Aerase, Inc.
Publication of PL3064579T3 publication Critical patent/PL3064579T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/50Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y305/00Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03001Arginase (3.5.3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
PL16163214T 2008-10-31 2009-11-02 Kompozycje farmaceutyczne i zastosowania medyczne uzyskanych metodami inżynierii ludzkich arginaz PL3064579T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11021808P 2008-10-31 2008-10-31
EP16163214.6A EP3064579B1 (en) 2008-10-31 2009-11-02 Pharmaceutical compositions and medical uses of engineered human arginases
EP09824219.1A EP2350273B1 (en) 2008-10-31 2009-11-02 Compositions of engineered human arginases and methods for treating cancer
PCT/US2009/062969 WO2010051533A2 (en) 2008-10-31 2009-11-02 Compositions of engineered human arginases and methods for treating cancer

Publications (1)

Publication Number Publication Date
PL3064579T3 true PL3064579T3 (pl) 2021-07-05

Family

ID=42129584

Family Applications (3)

Application Number Title Priority Date Filing Date
PL16163214T PL3064579T3 (pl) 2008-10-31 2009-11-02 Kompozycje farmaceutyczne i zastosowania medyczne uzyskanych metodami inżynierii ludzkich arginaz
PL20171935.8T PL3778885T3 (pl) 2008-10-31 2009-11-02 Kompozycje modyfikowanych ludzkich arginaz i sposoby leczenia raka
PL09824219.1T PL2350273T3 (pl) 2008-10-31 2009-11-02 Kompozycje modyfikowanych ludzkich arginaz i sposoby leczenia nowotworu złośliwego

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL20171935.8T PL3778885T3 (pl) 2008-10-31 2009-11-02 Kompozycje modyfikowanych ludzkich arginaz i sposoby leczenia raka
PL09824219.1T PL2350273T3 (pl) 2008-10-31 2009-11-02 Kompozycje modyfikowanych ludzkich arginaz i sposoby leczenia nowotworu złośliwego

Country Status (15)

Country Link
US (8) US8440184B2 (pl)
EP (5) EP2350273B1 (pl)
JP (2) JP5695570B2 (pl)
CA (1) CA2742497C (pl)
DK (3) DK3778885T3 (pl)
ES (3) ES2574139T3 (pl)
FI (1) FI3778885T3 (pl)
HK (1) HK1160165A1 (pl)
HR (1) HRP20230484T1 (pl)
HU (1) HUE062354T2 (pl)
LT (1) LT3778885T (pl)
PL (3) PL3064579T3 (pl)
PT (1) PT3778885T (pl)
SI (1) SI3778885T1 (pl)
WO (1) WO2010051533A2 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3778885T3 (fi) * 2008-10-31 2023-05-23 Aerase Inc Muokattujen ihmisen arginaasien koostumuksia ja menetelmiä syövän hoitamiseksi
US8679479B2 (en) * 2009-06-29 2014-03-25 Aerase, Inc. Methods for purifying pegylated arginase
WO2012061015A2 (en) * 2010-11-03 2012-05-10 Scott & White Healthcare L-citrulline supplementation during arginine depletion therapy with arginase
CN102234624B (zh) * 2011-04-25 2013-03-06 武汉远大弘元股份有限公司 一种表达产生枯草芽孢杆菌精氨酸酶的基因工程菌及构建方法
CN103184208B (zh) * 2011-12-27 2015-09-16 拜奥生物科技(上海)有限公司 人精氨酸酶和定点聚乙二醇化人精氨酸酶及其应用
WO2014003850A2 (en) * 2012-06-26 2014-01-03 Timothy Paul Foster Methods for treatment of ocular diseases
US9011845B2 (en) 2012-06-26 2015-04-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for treatment of inflammatory and infectious viral diseases
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
TWI708789B (zh) 2014-07-08 2020-11-01 開曼群島商瑞華藥業集團 精胺琥珀酸合成酶之抗體及相關方法
ES2909556T3 (es) 2016-08-08 2022-05-09 Aerase Inc Composiciones y procedimientos para el tratamiento de cáncer con agentes de disminución de arginina y de inmunoncología
KR102674521B1 (ko) * 2016-10-07 2024-06-11 아이오 바이오테크 에이피에스 면역원성 아르기나제 펩타이드
US20200150125A1 (en) 2017-03-12 2020-05-14 Yeda Research And Development Co., Ltd. Methods of diagnosing and prognosing cancer
WO2018167780A1 (en) 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
TW201910513A (zh) * 2017-08-16 2019-03-16 香港商鎧耀波麗堂(香港)有限公司 胺基酸耗竭治療的組合物及方法
EP3720476A1 (en) 2017-12-05 2020-10-14 AERase, Inc. Method and composition for treating arginase 1 deficiency
WO2020081994A1 (en) 2018-10-19 2020-04-23 Aerase, Inc. Arginine depletion therapy for treatment of gamt deficiency
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
CA3149592A1 (en) * 2019-08-30 2021-03-04 Scott W. Rowlinson Methods for production of human recombinant arginase 1 and uses thereof
WO2022195629A1 (en) * 2021-03-18 2022-09-22 National Institute Of Pharmaceutical Education And Research (Niper) Engineered arginase constructs, method of generation and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02117383A (ja) * 1988-10-26 1990-05-01 Tosoh Corp ヒトアルギナーゼの製造方法
US5780286A (en) * 1996-03-14 1998-07-14 Smithkline Beecham Corporation Arginase II
WO2003063780A2 (en) * 2002-01-25 2003-08-07 Cancer Treatments International Therapeutic composition for treatment of cancer by arginine depletion
HK1053577A2 (en) * 2002-06-20 2003-10-10 Bio Cancer Treatment Int Ltd Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation
CN1745847A (zh) * 2004-09-08 2006-03-15 康达医药科技有限公司 用精氨酸酶治疗肝炎的药物组合物和方法
FI3778885T3 (fi) * 2008-10-31 2023-05-23 Aerase Inc Muokattujen ihmisen arginaasien koostumuksia ja menetelmiä syövän hoitamiseksi

Also Published As

Publication number Publication date
EP2350273A4 (en) 2012-06-27
EP3778885A1 (en) 2021-02-17
US20190000939A1 (en) 2019-01-03
SI3778885T1 (sl) 2023-07-31
WO2010051533A2 (en) 2010-05-06
ES2945580T3 (es) 2023-07-04
US20210128703A1 (en) 2021-05-06
US20170128553A1 (en) 2017-05-11
PL2350273T3 (pl) 2016-10-31
EP3064579A1 (en) 2016-09-07
EP3957728A1 (en) 2022-02-23
CA2742497A1 (en) 2010-05-06
US20100111925A1 (en) 2010-05-06
US9050340B2 (en) 2015-06-09
PL3778885T3 (pl) 2023-07-03
USRE46423E1 (en) 2017-06-06
EP2350273A2 (en) 2011-08-03
EP2350273B1 (en) 2016-04-06
CA2742497C (en) 2024-01-23
EP3064579B1 (en) 2020-09-30
DK3778885T3 (da) 2023-05-30
HK1160165A1 (zh) 2012-08-10
ES2574139T3 (es) 2016-06-15
JP2014036676A (ja) 2014-02-27
EP3778885B1 (en) 2023-03-08
LT3778885T (lt) 2023-06-12
US20240009283A1 (en) 2024-01-11
DK2350273T3 (en) 2016-06-13
ES2838848T3 (es) 2021-07-02
DK3064579T3 (da) 2020-12-21
HUE062354T2 (hu) 2023-10-28
WO2010051533A3 (en) 2010-08-19
JP2012507301A (ja) 2012-03-29
HRP20230484T1 (hr) 2023-07-21
FI3778885T3 (fi) 2023-05-23
US20130273022A1 (en) 2013-10-17
PT3778885T (pt) 2023-05-31
US8440184B2 (en) 2013-05-14
US10098933B2 (en) 2018-10-16
EP3957727A1 (en) 2022-02-23
JP5695570B2 (ja) 2015-04-08
US20140242060A1 (en) 2014-08-28

Similar Documents

Publication Publication Date Title
PL3064579T3 (pl) Kompozycje farmaceutyczne i zastosowania medyczne uzyskanych metodami inżynierii ludzkich arginaz
IL276157A (en) Pharmaceutical preparations and methods for transferring them related to them
EP2262469A4 (en) SKIN CARE COMPOSITIONS AND METHODS OF USE
EP2498988A4 (en) MEDICAL ARTICLES AND METHODS OF MANUFACTURING USING MISCIBLE COMPOSITION
EP2322221A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CANCER
EP2528603A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS
IL206080A0 (en) Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases
EP2450046A4 (en) MEDICALLY ACTIVE COMPOSITION FOR THE TREATMENT OF BRONCHITIS AND PREPARATION THEREOF
IL210810A0 (en) Compositions for the treatment of pain and/or inflamtion
EP2432492A4 (en) APPLICATION AND USE OF PRG4 AND THERAPEUTIC MODULATION THEREOF
IL207546A0 (en) Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases
EP2170404A4 (en) COMPOSITIONS WITH HUMAN EGFR SIRNA AND METHOD OF USE
GB201302653D0 (en) Pharmaceutical compositions and methods of treatment
EP2651439A4 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HUMAN ADENOVIRUS 36 INFECTION
ZA201104882B (en) Pharmaceutical compositions with superior product performance and patient compliance
PT2474306T (pt) Composição particulada e composição medicinal que a compreende
EP2305300A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CANCER
IL219018A (en) Radzolid Pharmaceuticals and Uses
IL216529A0 (en) Pharmaceutical compositions comprising extracts of s arcopoterium spinosum, components thereof, and uses thereof
AU2007900995A0 (en) Therapeutic Compositions and Methods of Treatment